Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance InfrastructureJanuary 15, 2021ShareCategoriesPublic HealthIn the NewsCOVID-19Helix Partners